Skip to main content

Table 1 Selection criteria for HDACi

From: High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons

Molecule name

Selectivity

Development status

Maximum development phase

FDA approved

BBB penetration

Half-life (h)

Entinostat

HDAC 1, 3

Investigational

3

0

Limited/poor

33–150 [63]

JNJ-26481585

Pan HDAC

Investigational

2

0

Not reported

8,8 [64]

Pracinostat

Pan HDAC

Investigational

2

0

Yes in mice

5,6–8,9 [65]

Panobinostat

Pan HDAC

Marketed

4

1

Limited

16 [66]

Belinostat

Pan HDAC

Marketed

4

1

Limited

1,5 [67]

Trichostatin A

Pan HDAC

Investigational

1

0

Limited

Not determined

Givinostat

Pan HDAC

Investigational

3

0

Yes

6,9 [68]

Vorinostat

Pan HDAC

Marketed

4

1

Yes

1–2 [69]

Abexinostat

Pan HDAC

Investigational

1

0

Yes

4 [70]

CUDC-101

Pan HDAC, Her, EGFR

Investigational

1

0

Not reported

4,4 [71]

Dacinostat

Pan HDAC

Investigational

2

0

Not reported

6–15 [72]

Mocetinostat

Class I selective

Investigational

2

0

Yes in mice

7–11 [73]

CUDC-907

Pan HDAC, PI3K

Investigational

2

0

< 10% in mice

3 [74]

Resminostat

HDAC 1, 3, 6

Investigational

2

0

Not reported

3 [75]

Tacedinaline

Class I selective

Investigational

3

0

15–45% in monkey

8,5–10 [76]

RG2833

HDAC 1, 3

Investigational

1

0

Yes in mice

6–10 [77]

M344

Pan HDAC

Discovery

 

0

Yes in mice

Not determined

Domatinostat

Pan HDAC, LSD1

Investigational

1

0

Not reported

20 [78]

Scriptaid

Pan HDAC

Discovery

 

0

Not reported

Not determined

Rocilinostat

HDAC 6

Investigational

2

0

Not reported

3 [79]